Teva Pharmaceutical Industries LTD 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
Teva Pharmaceutical Industries Limited reported a 4% increase in 2025 revenues, driven by strong performance in key innovative products and strategic pipeline advancements, despite declines in certain generic markets.
NYSE
Teva Pharmaceutical Industries navigates a year of strategic transformation, showcasing growth in key products but facing challenges in generics and legacy treatments.
NYSE
10-K: Teva Pharmaceuticals Extends Executive Assignment and Details Financial Revisions in 10-K Filing
Teva Pharmaceuticals extends an executive's international assignment and revises prior financial statements, highlighting a collaboration payment and sustainability-linked bond details.